OncoMatch/Clinical Trials/NCT07192614
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
Is NCT07192614 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies AZD6621 for prostate cancer.
Treatment: AZD6621 — This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD6621. The study is split into different modules which will look at AZD6621 delivered by different methods. The study is also further split into 2 parts, Part A which will test different dose levels of AZD6621 to determine which doses are the best in terms of safety and side effects (dose escalation), and Part B will further test at least two AZD6621 doses in a larger group of participants (dose expansion).
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Biomarker criteria
Required: AR castration (testosterone ≤ 50 ng/dL) (testosterone ≤ 50 ng/dL (≤ 1.75 nmol/L))
Surgically or medically castrated, with serum testosterone levels ≤ 50 ng/dL (≤ 1.75 nmol/L) ≤ 28 days before first dose of study intervention
Required: AR castration-resistant (disease progression despite castration by orchiectomy or ongoing ADT)
Castration-resistant prostate cancer as defined by disease progression despite castration by orchiectomy or ongoing ADT
Required: KLK3 PSA ≥ 1 ng/mL (PSA ≥ 1 ng/mL)
PSA at screening visit ≥ 1 ng/mL
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: CAR-T cell therapy
CAR-T cell therapy within the last 6 months prior to enrolment on this study.
Lab requirements
Blood counts
Adequate hematological and bone marrow function as documented in the protocol
Kidney function
Adequate renal function as documented in the protocol
Liver function
Adequate liver function as documented in the protocol
Cardiac function
Mean resting corrected QT interval ≤ 470 ms; LVEF ≥ 50% on screening cardiac MUGA or ECHO
Adequate hematological, renal, bone marrow, and liver function as documented in the protocol. Mean resting corrected QT interval > 470 ms [excluded]. Inadequate cardiac function of LVEF < 50% on screening cardiac MUGA or ECHO [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Orlando, Florida
- Research Site · Tampa, Florida
- Research Site · Boston, Massachusetts
- Research Site · Grand Rapids, Michigan
- Research Site · Commack, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify